Combination treatment with guselkumab (Tremfya) plus golimumab (Simponi) may hold an advantage over use of either agent alone for patients with moderate-to-severe ulcerative colitis, results from a ...

CHARLOTTE, NC — People with moderate-to-severe ulcerative colitis benefit from stronger treatment from the start — a combination of monoclonal antibodies — compared with induction with either agent ...

https://www.tipranks.com/news/the-fly/evofem-says-fda-orange-book-lists-patent-for-solosec-treatment-thefly The U.K.’s Medicines and Healthcare products Regulatory ...

Please provide your email address to receive an email when new articles are posted on . Guselkumab produced consistent effects among biologic-naïve patients with PsA and those responded inadequately ...